Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

15.52 -0.68 (-4.20%)
Streaming Delayed Price Updated: 11:06 AM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 550,281
Open 16.28
Bid (Size) 15.48 (2)
Ask (Size) 15.52 (3)
Prev. Close 16.20
Today's Range 15.42 - 16.48
52wk Range 8.580 - 22.50
Shares Outstanding 69,484,053
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+10.2%
+10.2%
1 Month
-2.6%
-2.6%
3 Month
+58.0%
+58.0%
6 Month
+47.5%
+47.5%
1 Year
-15.3%
-15.3%

More News

Read More
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For August 4, 2025
Via Benzinga
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth
Via Benzinga
This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Deep Dive Into Syndax Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
Syndax Announces Participation in September Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Pharmaceuticals's Earnings: A Preview
Via Benzinga
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax (SNDX) Q2 Revenue Jumps 986%
Via The Motley Fool
Topics Intellectual Property
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q2 2025 Earnings with Revenue Beat and Narrower EPS Loss
Via Chartmill
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Announces Participation in June Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Announces Participation in May Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Syndax Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Syndax Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Syndax Pharmaceuticals, Inc. - Common Stock trade on?
Syndax Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock is SNDX on the Nasdaq Stock Market
What is the current price of Syndax Pharmaceuticals, Inc. - Common Stock?
The current price of Syndax Pharmaceuticals, Inc. - Common Stock is 15.52
When was Syndax Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Syndax Pharmaceuticals, Inc. - Common Stock was at 10/10/25 11:06 AM ET
What is the market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock is 1.08B
How many shares of Syndax Pharmaceuticals, Inc. - Common Stock are outstanding?
Syndax Pharmaceuticals, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.